Clinical Trial Update: Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Atrasentan in Pediatric Patients With Primary IgAN [Phase 3]

View source ↗

Summary

Phase 3 pediatric trial evaluating atrasentan for efficacy, pharmacokinetics, safety and tolerability in primary IgA nephropathy; the study is not yet recruitin…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Iga Nephropathy

Drugs mentioned

• Atrasentan (atrasentan)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Berger Disease, Bergers Disease | Phase 3 | Status: NOT_YET_RECRUITING